This study encompassed 1,136,016 US patients diagnosed with invasive BC between January 1, 2010, and December 31, 2019, who exhibited ERBB2-negative disease and had accessible immunohistochemistry results [55]. The gene discussed is ERBB2; the disease is breast cancer.